FSI Network

BioXpress

The MAb-based drug market is one of the fastest growing categories of the biopharmaceuticals industry. These products are of high value for pharmaceutical industry, both in research as well as drug development activities.

Biosimilar biologics are complex protein structures. The highly experienced BioXpress Therapeutics team has worked on the development of 12 originator MAbs currently on the market. Since Q2 2010, BioXpress Therapeutics has completed the validation of protein sequence, cell line development, analysis of production cell line, and pre-Phase I clinical plans for its first four biosimilar MAbs: adalimumab, bevacizumab, rituximab and trastuzumab.

Each BioXpress Therapeutics monoclonal antibody (MAb) biosimilar drug is developed under strict non-clinical and clinical guidelines as outlined in the European Medicines Agency’s “Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies.” Furthermore, each BioXpress Therapeutics biosimilar goes through a complete analytical comparison to determine the product is similar to the innovator product.

To ensure BioXpress Therapeutics has identified the best opportunity within the MAb biosimilar arena, the Company has developed a proprietary database of twenty-five data points for each drug, based on comprehensive analysis of literature and patent databases. All data entry and data analysis is done by the Company’s team, which consists of scientists who have been actively involved in making monoclonal antibody therapeutics since the early 1980s. As a result, the BioXpress scientific team is well versed in the literature and groups who have developed many of the originator MAbs over the decades.

website: www.bioxpress.com

CellNTech

Medimaps

Searchbox

Today’s information is highly complex and unstructured: emails, contracts, publications, word/pdf documents. Most systems struggle to understand the context because of keyword limitations. As such, professionals are facing problems when trying to search, access and organize this maze of information.

salsaDev understands information in a similar way as humans, based on their actual concept(s) – far outpacing keyword restricted systems. After indexing, salsaDev provides a complete set of functionalities, including enterprise search, automatic categorization, information access and semantic lifting. See below for more details.

Developed from advanced research at the Rensselaer Polytechnic Institute (Troy, NY), the salsaDev technology significantly improves the way people find information, by providing software that reads and understands various sources of documents (from structured to fully unstructured raw information).

This groundbreaking technology, developed by acknowledged experts, combines Language Acquisition techniques and Latent Semantic Analysis (LSA) to form a conceptual and contextual understanding of any piece of textual information. The technology is inspired from vector-based computation and statistical analysis.

The salsaDev difference is in our ability to mathematically convert data into a concise conceptual semantic form, and thus swiftly provide highly pertinent related results which are often not visible in the mounds of data with traditional researching techniques.

website: www.salsadev.com

InZair

ZMS is the next generation mobile messaging. It’s smarter than SMS and cheaper than MMS.

“As much as we appreciate the simplicity of SMS and the richness of MMS, we thought we could offer much more and help consumers to easily engage, surprise, inform friends and others in the right place, at the right time.

As the new and interactive mobile messaging platform, inZair allows anyone with a smartphone to freely send and receive ZMS, known as smart multimedia messages, using the benefit of geo-localisation and time, based on strong geo-location integration and full respect of consumer privacy.

In a nutshell, ZMS is free, smart, easy and interactive – it works with people’s mobile address book and allows them to use their mobile wifi or their existing mobile data connection to share text, audio, pictures video and even location, with one person or more and at no extra cost. It also enables users to drop a message to someone on a map in a specific location or schedule it at a specific time.

ZMS is being used in people’s daily life for a wide range of activities, including:

  • Sharing text, photo, audio, video content from your phone in real-time
  • As a reminder for your girlfriend’s birthday
  • Sharing location to reassure a close one
  • Finding a a friend at a crowded concert
  • Surprising a loved one with a geo-localised ZMS message
  • Sharing and organizing dinner plans with a group of friends
  • Discovering new things around you and meet new people with similar interests, in real-time

InZair also enables businesses and brands to engage people in a very effective and targeted way. inZair was founded in 2010 and has offices at Fongit. Come and visit.

ZMS is currently available on the App store and will soon be available on the Android platform.

Website: www.inzair.com

Viroblock

Viroblock SA is a start up focused on developing and out-licensing anti-viral products.  Our core technology uses catalytic vesicles to inactivate a broad spectrum of enveloped viruses such as human and avian influenzas, SARS, HIV, Ebola, Marburg and Smallpox viruses.  In-vitro and in-vivo testing on model systems has validated the technology and the company is now focused on developing a pre-impregnated anti-viral mask for launch in 2012. The venture is supported by CTI Start-up and FONGIT.

Viroblock’s catalytic vesicles can be formulated into gels, creams, and sprays or coated onto fabrics. The first commercial product will be an antiviral mask offering viral kill on pass through air. This product has use in a wide variety of Healthcare, Public Health, Homeland Security, Biodefense and Veterinary situations. Revenue streams will be generated via licenses and royalties.

The spectrum and fast acting anti-viral technology offers the possibility to make unique viral kill claims on pass through air (mask product). Flexible and robust technology offering multiple product executions – masks, air filtration products, anti-viral fabrics, nasal sprays, vaginal gels, and so forth.

website: www.viroblock.com

 

Selexis

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.

Founded in 2001, the Company is dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (e.g. monoclonal antibodies (MAbs), growth factors, enzymes).

The Selexis SUREtechnology Platform™ improves the way cells are used in the discovery, development and manufacturing of recombinant protein drugs by providing key significant advantages over traditional approaches. The SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The Selexis SUREtechnology Platform™ provides users a single platform that can be used for a wide range of applications from late R&D to biologics manufacturing including target discovery, cell-based assays, protein production for discovery and pre-clinical studies, diagnostics, bio-manufacturing of therapeutic proteins.

As of 4Q2011, Selexis has generated over 1,300 clonal cell lines being used in a variety of programs from discovery to late-stage clinical trials. More than 20 Selexis cell lines are in clinical trials and the Company anticipates several products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.

Website: www.selexis.com

Anteis

Based in Geneva, Switzerland, with roughly 150 employees and manufacturing facilities in two Swiss locations, Anteis distributes products to over 95 countries worldwide. The company has grown strongly since its establishment in 2003, and has a robust pipeline of products and technologies. It holds numerous patents and has over solid pipeline of new products in development or awaiting clinical trials.  Its vision is to offer life-changing solutions to meet the needs of doctors and their patients worldwide. It is committed to investing in constant improvement and innovation, and is dedicated to being a reliable partner for doctors and their patients by providing the best possible products, supported by state-of-the-art injection systems and superior training and information.

Anteis is a company focused on innovation, which drives its strong growth and hence devotes a substantial share of its revenue to R&D (equivalent to 11% in 2011). The Research and Development department brings together a multidisciplinary team made up of chemists, biochemists and physicists working in numerous laboratories focused on: chemical transformation and formulation of biopolymers, physical-chemical and microbiological characterization of prototypes, optimization of manufacturing processes, and design and improvement of injection devices.

Since 2005, Anteis has been constantly developing and launching products for the aesthetic dermatology market and it founded, in 2007, its own academy (InjectNow Academy) that enables practitioners, whatever their profile, unique opportunities to improve their level of expertise. Anteis has developed four totally complementary product ranges that permit practitioners to smooth, fill, model and rehydrate the dermis to perfection.

In 2007, the Anteis group created its Ophthalmology department, focusing on applications and devices designed to meet the requirements of this medical-surgical speciality. The Anteis policy is twofold: (i) developing viscoelastic products (OVD) adapted to different eye surgery programs and (ii) designing devices capable of treating major pathologies of the eye’s anterior segment. In the beginning of next year, Anteis will launch a drainage viscoelsatic injectable implant, presented in a glass syringe, indicated as an adjuvant during perforating and non-perforating glaucoma surgery.

It new flag product, Synolis V-A, is an innovative, new-generation treatment for osteoarthritis that provides rapid pain relief. The treatment consists of 3 injections administered over 3 weeks. It shows excellent safety and tolerability. Osteoarthritis, also known as degenerative arthritis, is a painful and potentially immobilizing condition caused by the degeneration and loss of cartilage in one or more joints.

Website: www.anteis.com

Aimago